Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

Conferencesofetabart mipitecanolomorasibPositive

AI Analysis

Summary

Lilly announced it will present oncology pipeline data at ESMO 2026, including first Phase 1 data for FRα-targeting ADC sofetabart mipitecan in platinum-sensitive ovarian cancer and updated first-line data for KRAS G12C inhibitor olomorasib in NSCLC.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Lilly to present first Phase 1 data for sofetabart mipitecan (FRα-targeting ADC) in platinum-sensitive ovarian cancer in a rapid oral presentation, and updated first-line data for olomorasib in KRAS G12C-mutant NSCLC, at the 2026 ESMO Congress.

Importance:5/10

Sentiment:

0.30

ESMOoncologyADCovarian cancerNSCLCKRAS G12CFRαconferencePhase 1

Related Companies

$LLY

Read the original article

Published by PR Newswire Biotech on October 18, 2026 10:05 PM

Read Original